Download Traitement Cancer Sein Mг©tastatique Pdf Apr 2026

Usually a combination of an aromatase inhibitor (or fulvestrant) and a CDK4/6 inhibitor (such as palbociclib, ribociclib, or abemaciclib).

Treatment decisions are primarily driven by the tumor's biological profile, specifically Hormone Receptor (HR) and HER2 status. HR-Positive, HER2-Negative (Luminal) Download Traitement cancer sein mГ©tastatique pdf

This remains the most common subtype, representing approximately 70–75% of cases. Usually a combination of an aromatase inhibitor (or

For patients with ESR1 mutations , newer oral selective estrogen receptor degraders (SERDs) like elacestrant are increasingly utilized. HER2-Positive SENORIF 2025-2026 - Institut Curie Download Traitement cancer sein mГ©tastatique pdf

As of early 2026, the European Commission approved inavolisib (Itovebi) for use in combination with palbociclib and fulvestrant for advanced forms of the disease.